« Zurück
Home /
Reparixin (L-lysine salt)

Reparixin (L-lysine salt)

ArtNr	HY-15252-50mg
Hersteller	MedChem Express
CAS-Nr.	266359-93-7
Menge	50 mg
Quantity options	100 mg 10mM/1mL 10 mg 25 mg 2 mg 50 mg 5 mg
Kategorie	Neuroscience Neuroinflammation Metabolism Diabetes Inhibitors & Compound Libraries Small Molecules
Typ	Inhibitors
Clon	N/A
Specific against	other
Purity	99.66
Formula	C20H35N3O5S
Citations	Ann Rheum Dis. 2016 Apr;75(4):721-9.<br/>Biomed Res Int. 2020 Aug 5;2020:4670604.<br/>bioRxiv. 2020 Sep 12;2020.08.25.265561.<br/>Neurobiol Dis. 29 October 2021, 105538.<br/>Patent. US20170105971A1.<br/>Patent. US20170181987A1.<br/>Ann Rheum Dis. 2016 Apr;75(4):730-8.<br/>Biochim Biophys Acta. 2017 Jan;1863(1):220-230.<br/>bioRxiv. 2024 Feb 1.<br/>BMC Med. 2022 Feb 8;20(1):55.<br/>Cancer Cell Int. 2021 Jul 3;21(1):337.<br/>Cancer Cell. 2023 Apr 10;41(4):693-710.e8.<br/>Cancers (Basel). 2023 Sep 4;15(17):4422.<br/>Cell Biosci. 2019 Jan 3;9:4. <br/>Cell Commun Signal. 2023 Mar 13;21(1):59.<br/>Cell Death Dis. 2017 Jul 13;8(7):e2932.<br/>Cell Mol Gastroenterol Hepatol. 2024 May 7:S2352-345X(24)00105-X.<br/>Cells. 2022 Jun 21;11(13):1986.<br/>Cells. 2022, 11(15), 2402.<br/>EBioMedicine. 2019 May;43:487-500. <br/>FACETS. 2020 Jul.<br/>Front Immunol. 17 October 2022.<br/>Front Immunol. 2021 May 7;12:667177.<br/>Front Immunol. 2018 Sep 12;9:2058.<br/>Gene. 2018 Nov 30;677:149-162.<br/>J Allergy Clin Immunol. 2018 Jun;141(6):2286-2289.e5.<br/>J Cell Mol Med. 2020 Jan;24(2):1588-1598.<br/>J Cell Mol Med. 2020 Nov;24(21):12608-12618.<br/>J Gastroenterol Hepatol. 2018 Feb;33(2):431-442.<br/>J Immunol. 2018 Jul 15;201(2):814-820. <br/>J Mol Cell Biol. 2023 Apr 18;mjad025.<br/>J Mol Med (Berl). 2019 Jan;97(1):25-35. <br/>Johns Hopkins University. Department of Chemical and Biomolecular Engineering. 2016 Dec.<br/>Karolinska Institutet. Dept of Physiology and Pharmacology. 2022 Feb.<br/>Mol Immunol. 2018 Aug 7;101:440-449. <br/>Mol Ther. 2022 Jul 14;S1525-0016(22)00429-4.<br/>Nat Commun. 2017 May 26;8:15584.<br/>Oncogenesis. 2016 Jun 13;5(6):e234. <br/>Oncotarget. 2017 Jul 21;8(36):60210-60222.<br/>Oncotarget. 2018 Aug 24;9(66):32556-32569. <br/>Patent. US20220251222A1.<br/>Research Square Preprint. 2021 Mar.<br/>Research Square Preprint. 2022 Jan.<br/>Sci Adv. 2019 May 8;5(5):eaav7384.<br/>Sci Rep. 2017 Nov 6;7(1):14510. <br/>Stem Cells. 2015 Dec;33(12):3558-68. <br/>University of Michigan. 2018 Oct.<br/>Vet Immunol Immunopathol. 2016 Dec;182:52-58. <br/>Xenotransplantation. 2018 Mar;25(2):e12385.<br/>[1]Moriconi A, et al. Design of noncompetitive interleukin-8 inhibitors acting on CXCR1 and CXCR2. J Med Chem. 2007 Aug 23;50(17):3984-4002.<br/>[2]Bertini R, et al. Receptor binding mode and pharmacological characterization of a potent and selective dual CXCR1/CXCR2non-competitive allosteric inhibitor. Br J Pharmacol. 2012 Jan;165(2):436-54.<br/>[3]Midgley I, et al. Species differences in the pharmacokinetics and metabolism of reparixin in rat and dog. Xenobiotica. 2006 May;36(5):419-40<br/>[4]Catrina, Anca, et al. METHODS AND COMPOUNDS FOR THE TREATMENT OF BONE LOSS AND/OR PAIN. US 20170105971 A1.<br/>[5]Bertini R, et al. Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11791-6.
Smiles	N[C@@H](CCCCN)C(O)=O.CS(=O)(NC([C@@H](C1=CC=C(CC(C)C)C=C1)C)=O)=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	Repertaxin L-lysine salt
Lieferbar
Product Description	Reparixin L-lysine salt is an allosteric inhibitor of chemokine receptor 1/2 (CXCR1/2) activation.
StorageTemperature	4°C (Powder, sealed storage, away from moisture)
Shipping	Room Temperature
Manufacturers Applications	COVID-19-immunoregulation
MolecularWeight	429.57
Clinical Information	Phase 3
Manufacturers Research Area	Cancer; Inflammation/Immunology; Endocrinology
Solubility	DMSO : 100 mg/mL (ultrasonic)\|H2O : 100 mg/mL (ultrasonic)
Target	CXCR
Manufacturers Target	CXCR
Isoform	CXCR1; CXCR2
Manufacturers Pathway	GPCR/G Protein; Immunology/Inflammation
Manufacturers Product type	Reference compound

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkdatenblatt anfordern

HY-15252-50mg-safety-datasheet.pdf